MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage many intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Main trial objectives were To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis patients, whilst one of many exploratory targets https://lefamulinacetate88765.blogerus.com/53453821/not-known-facts-about-yx-2-107